Evidence map›Paper›PMID 41685161›Full record

ArticleActa pharmaceutica Sinica. B2026

A novel fusion protein of COVID-19 virus enhancing protection of Syrian hamsters infected with SARS-CoV-2.

Hanlu Wang, Tiantian Yang, Yichao Yan, Fengmei Yang, Xunhuan Song, Shuning Zhang, Wenhong Jiang, Mingxue Li, Wenting Sun, Yanyan Li and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta pharmaceutica Sinica. B, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Hanlu WangBiopharmaceutical R&D Center, Chinese Academy of Medical Sciences, Peking Union Medical College, Suzhou 215126, China.
Tiantian YangBiopharmaceutical R&D Center, Chinese Academy of Medical Sciences, Peking Union Medical College, Suzhou 215126, China.
Yichao YanBiopharmagen Corp., Suzhou 215126, China.
Fengmei YangInstitute of Medical Biology, Chinese Academy of Medical Sciences, Peking Union Medical College, Yunnan Key Laboratory of Vaccine Research Development on Severe Infectious Disease, Medical Primate Research Center, Kunming 650118, China.
Xunhuan SongDepartment of Lung Cancer Center and Center for Preclinical Safety Evaluation of Drugs, West China Hospital, Sichuan University, Chengdu 610041, China.
Shuning ZhangBiopharmagen Corp., Suzhou 215126, China.
Wenhong JiangBiopharmagen Corp., Suzhou 215126, China.
Mingxue LiInstitute of Medical Biology, Chinese Academy of Medical Sciences, Peking Union Medical College, Yunnan Key Laboratory of Vaccine Research Development on Severe Infectious Disease, Medical Primate Research Center, Kunming 650118, China.
Wenting SunInstitute of Medical Biology, Chinese Academy of Medical Sciences, Peking Union Medical College, Yunnan Key Laboratory of Vaccine Research Development on Severe Infectious Disease, Medical Primate Research Center, Kunming 650118, China.
Yanyan LiInstitute of Medical Biology, Chinese Academy of Medical Sciences, Peking Union Medical College, Yunnan Key Laboratory of Vaccine Research Development on Severe Infectious Disease, Medical Primate Research Center, Kunming 650118, China.
Weihua JinInstitute of Medical Biology, Chinese Academy of Medical Sciences, Peking Union Medical College, Yunnan Key Laboratory of Vaccine Research Development on Severe Infectious Disease, Medical Primate Research Center, Kunming 650118, China.
Suqin DuanInstitute of Medical Biology, Chinese Academy of Medical Sciences, Peking Union Medical College, Yunnan Key Laboratory of Vaccine Research Development on Severe Infectious Disease, Medical Primate Research Center, Kunming 650118, China.
Meng QinBiopharmaceutical R&D Center, Chinese Academy of Medical Sciences, Peking Union Medical College, Suzhou 215126, China.
Zhanlong HeInstitute of Medical Biology, Chinese Academy of Medical Sciences, Peking Union Medical College, Yunnan Key Laboratory of Vaccine Research Development on Severe Infectious Disease, Medical Primate Research Center, Kunming 650118, China.
Yongping JiangBiopharmaceutical R&D Center, Chinese Academy of Medical Sciences, Peking Union Medical College, Suzhou 215126, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

COVID-19 and its variants have spread around the world, triggering a range of long-term sequelae and leading to the need for broadly effective vaccines. We have established a new fusion protein combining the receptor-binding domain region (SF2) and a newly identified conserved binding region (SF5) from the spike of SARS-CoV-2. This fusion protein (COVID19-SF2+SF5) specifically bound to VERO-E6 cells with higher efficiency than either region alone. Antibodies raised in mice against COVID19-SF2+SF5 cross-reacted with every fragment of SARS-CoV-2 and SARS. Additionally, antibodies against the fusion protein effectively neutralize pseudoviruses of both wild-type and mutant strains of SARS-CoV-2 (including BA.3, XBB.1.5, and EG.5), as well as SARS pseudoviruses. Protein interaction prediction and binding affinity determination revealed that the fusion protein exhibits strong binding capacity to three key host molecules: heparan sulfate proteoglycan (HSPG), neuropilin-1 (NRP1), and cluster of differentiation 147 (CD147). Analysis of representative viruses from four coronavirus genera (

Indexed as

Common binding regionConserve regionFusion proteinImmunizationProtectionSyndrome coronavirus 2 (SARS-CoV-2)

Identifiers

PMID41685161
PMCPMC12891839

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.